info@seagull-health.com
SeagullHealth
语言:
search
new
Indications for Safinamide (Xadago)
501
Article source: Seagull Pharmacy
Sep 12, 2025

Safinamide (Xadago) is a selective monoamine oxidase type B (MAO-B) inhibitor, used as an adjunctive medication for the treatment of Parkinson's disease. It was first approved for marketing by the U.S. FDA in 2017. This product must be used in combination with levodopa/carbidopa to treat the "off" episodes in patients with Parkinson's disease.

Indications for Safinamide (Xadago)

Adjunctive Treatment of Parkinson's Disease

The core indication of Safinamide (Xadago) is to serve as an adjunct to levodopa/carbidopa, for patients with Parkinson's disease (PD) who are experiencing "off" episodes.

The so-called "off" episodes refer to the phase of worsening motor function in Parkinson's disease patients when the effect of drug treatment diminishes.

Clinical studies have confirmed that safinamide can significantly increase the patients' "on" time (periods with well-controlled symptoms) while reducing the "off" time.

Dosage Form, Strength and Composition of Safinamide (Xadago)

Dosage Form and Strength

50 mg tablets: Orange-copper colored with a metallic luster, round and biconcave, imprinted with "50" on one side, and approximately 7 mm in diameter.

100 mg tablets: Orange-copper colored with a metallic luster, round and biconcave, imprinted with "100" on one side, and approximately 9 mm in diameter.

Composition

Each safinamide tablet contains the active ingredient safinamide mesylate, whose chemical name is (S)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]aminopropanamide methanesulfonate (1:1).

Its molecular formula is C₁₇H₁₉FN₂O₂•CH₄O₃S, with a molecular weight of 398.45.

Inactive ingredients include: microcrystalline cellulose, crospovidone, colloidal silicon dioxide, magnesium stearate, hypromellose, polyethylene glycol 6000, iron oxide red, potassium aluminum silicate, and titanium dioxide.

Storage Method for Safinamide (Xadago)

Storage Conditions

Safinamide tablets should be stored at 25°C (77°F), with a permitted brief fluctuation range between 15°C and 30°C (59°F and 86°F).

The original packaging must be kept tightly sealed to protect from moisture and direct sunlight.

Precautions

The medication should always be stored in the original packaging bottle until it is taken out for administration.

Do not use pill boxes or pill organizers for storage.

Keep the medication out of the reach of children.

Avoid storage in humid environments such as bathrooms.

Expired or no longer needed medications should be properly disposed of in accordance with local regulations.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
Recommended Articles
What Are the Side Effects of Echinocandin Capsules (Cresemba)?
Echinocandin Capsules (Cresemba) is an azole antifungal medication. For patients taking this drug, it is crucial to understand its potential side effects, severe adverse reactions that require vigilan...
How Effective is Isavuconazonium Sulfate Capsules (Cresemba) in Treatment?
Isavuconazonium Sulfate Capsules (Cresemba) is a broad-spectrum triazole antifungal drug, with isavuconazole as its active ingredient. As a new type of antifungal agent, Cresemba demonstrates unique a...
Precautions for Administration of Isavuconazonium Sulfate Capsules (Cresemba)
Isavuconazonium Sulfate Capsules (Cresemba) is a triazole antifungal drug. As a new-generation broad-spectrum antifungal agent, it exerts its antifungal effect by inhibiting the biosynthesis of ergost...
How to Use Isavuconazonium Sulfate Capsules (Cresemba)
Isavuconazonium Sulfate Capsules (Cresemba) is a triazole antifungal drug primarily indicated for the treatment of invasive aspergillosis and mucormycosis.How to Use Isavuconazonium Sulfate Capsules (...
How to Use Safinamide (Xadago)
Safinamide (Xadago) is a type B monoamine oxidase (MAO-B) inhibitor. It is used as an adjunctive therapeutic agent to levodopa/carbidopa for the treatment of "off" period symptoms in patient...
Precautions for Safinamide (Xadago) Administration
Safinamide (Xadago) is a selective monoamine oxidase type B (MAO-B) inhibitor. It was approved for marketing by the U.S. FDA in 2017 and is used as an adjunctive treatment for Parkinson's disease ...
How Effective is Safinamide (Xadago) in Treatment?
Safinamide (Xadago) is a selective monoamine oxidase type B (MAO-B) inhibitor. Used as an adjunctive therapeutic agent to levodopa/carbidopa, it is indicated for improving "off" period sympt...
What Are the Side Effects of Safinamide (Xadago)?
Safinamide (Xadago) is a type B monoamine oxidase (MAO-B) inhibitor. Used as an adjunctive therapeutic agent to levodopa/carbidopa, it is indicated for the treatment of "off" episodes in pat...
Related Articles
Dosage and Administration, Recommended Dose of Elacestrant (Orserdu)
Elacestrant (Orserdu) is a selective estrogen receptor degrader (SERD), which provides an important treatment option for patients with estrogen receptor-positive, HER2-negative advanced or metastatic ...
What Are the Indications for Elacestrant (Orserdu)?
Elacestrant (Orserdu) is a novel endocrine therapy agent that demonstrates significant value in the treatment of advanced breast cancer with specific gene mutations. As an estrogen receptor antagonist...
What Are the Purchase Channels for Elacestrant (Orserdu)?
With the advancement of medical technology, elacestrant (Orserdu), a targeted drug for breast cancer with specific gene mutations, has brought new treatment options for patients. As the first oral sel...
Adverse Reactions of Capmatinib (Tabrecta)
Capmatinib (Tabrecta) is a highly selective MET inhibitor indicated for the treatment of patients with advanced non-small cell lung cancer harboring MET gene mutations. By precisely inhibiting the act...
What are the Precautions for Capmatinib (Tabrecta) Administration?
Capmatinib (Tabrecta) is a targeted therapy drug for MET gene mutations, demonstrating significant efficacy in the treatment of advanced malignancies such as non-small cell lung cancer.What are the Pr...
Dosage and Administration, Recommended Dosage of Capmatinib (Tabrecta)
Capmatinib (Tabrecta) is a highly selective MET inhibitor, offering a precision treatment option for patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutation...
What Are the Indications for Capmatinib (Tabrecta)?
Capmatinib (Tabrecta) is a targeted therapy medication that plays an important role in the treatment of non-small cell lung cancer associated with specific gene mutations. As a MET kinase inhibitor, i...
What Are the Purchase Channels for Capmatinib (Tabrecta)?
Capmatinib (Tabrecta) is a highly selective MET inhibitor that has demonstrated significant efficacy in patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutat...
New Drugs
Infigratinib(Truseltiq)
Infigratinib(Truseltiq)
Treatment of previously treated, unresectable locally advanced or metastatic...
Opicapone(Ongentys)
Opicapone(Ongentys)
Adjunctive treatment to levodopa/carbidopa for reducing "off" episodes in...
Deflazacort(Emflaza)
Deflazacort(Emflaza)
Treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and...
Faricimab-svoa(Vabysmo)
Faricimab-svoa(Vabysmo)
Treatment of neovascular age-related macular degeneration, diabetic macular...
Counselling Service
Global Drug Search
Clinical Research Recruitment
Overseas Medical Treatment
Remote Consultations
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Submit
Business
  • Core products
  • Antitumor drugs
  • General drug
  • Antiviral drugs
  • Biological agents
Contact Us 
  • mailbox:info@lucius.la
Welcome to consult
ucius Pharmaceuticals (Lao) Co.,Ltd All rights reserved